MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 349-354

  Yu, Xiu Yue ^a   Zhang, Zhe ^a   Liu, Jiao ^a   Zhan, Bo ^a   Kong, Chui Ze ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

769 P; Carcinogenesis; Luciferase; MicroRNAs; Proliferation; Target

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CELL DIVISION CYCLE 25B PHOSPHATASE; MICRORNA 141; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MOLECULAR INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION ELONGATION; TRANSCRIPTION REGULATION; VALIDATION PROCESS;

EID: 84876356152     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S41343     Document Type: Article

References (23)

1. Young AN, Master VA, Paner GP, Wang MD, Amin MB. Renal epithelial neoplasms: diagnostic applications of gene expression profiling. Adv Anat Pathol. 2008;15(1):28-38.
2. Leroy X, Zini L, Buob D, Ballereau C, Villers A, Aubert S. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. Arch Pathol Lab Med. 2007;131(1):102-106.
3. Kardas I, Mrózek K, Babinska M, et al. Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep. 2005;13(5): 949-956.
4. Girolami F, Passerini I, Gargano D, et al. Microsatellite analysis of chromosome 3p region in sporadic renal cell carcinomas. Pathol Oncol Res. 2002;8(4):241-244.
5. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006;18(2):185-191.
6. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7(7): 495-507.
7. Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B. Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene. 2001;20(8):921-932.
8. Gabrielli B., De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci. 1996;109(Pt 5):1081-1093.
9. Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25B and cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999;146(3):573-584.
10. Löffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Krämer A. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle. 2006;5(21):2543-2547.
11. van Vugt MA, Brás A, Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15(5):799-811.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
13. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102-114.
14. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-840.
15. Carthew RW. Gene regulation by microRNAs. Curr Opin Genet Dev. 2006;16(2):203-208.
16. Drakaki A, Iliopoulos D. MicroRNA gene networks in oncogenesis. Curr Genomics. 2009;10(1):35-41.
17. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol. 2006;58 Suppl 1:S63-S68.
18. Dorris ER, Smyth P, O'Leary JJ, Sheils O. MIR141 expression differentiates Hashimoto thyroiditis from PTC and benign thyrocytes in Irish archival thyroid tissues. Front Endocrinol (Lausanne). 2012;3:102.
19. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol. 2011;5(3): 281-291.
20. Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer. 2010; 10:233.
21. Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev. 2012;13(3):931-935.
22. Liffers ST, Munding JB, Vogt M, et al. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest. 2011;91(10): 1472-1479.
23. Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B. Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther. 2006;5(6):1446-1451.